Treats intermediate or high-risk primary or secondary (post-polycythemia vera or…. Sold as Vonjo. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Pacritinib Citrate (sold as Vonjo), first approved Feb 28, 2022, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Vonjo | Part D | $129M | +16% | 1,153 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström MacroglobulinemiaWaldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma · Shayna Sarosiek, MD | Phase 2 | Recruiting | May 22, 2025 |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia MyelofibrosisPrimary Myelofibrosis, Post-polycythemia Vera Myelofibrosis · Swedish Orphan Biovitrum | Phase 3 | Active, not recruiting | May 24, 2017 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA